Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — H1 FY26 Earnings Presentation
26 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Nov 13, 2025
Slide 1: Regulation 30 Disclosure Letter to Stock Exchanges
Ref: Akums/Exchange/2025-26/56 November 13, 2025 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, Rotunda Building, Phiroze Jeejeebhoy Bandra Kurla Complex, Towers, Dalal Street, Fort, Mumbai – Bandra (E),Mumbai – 40
Slide 2: Q2 and H1FY 25-26 Earnings Presentation
Q2 and H1FY 25-26 Earnings Presentation Nov 2025
Slide 3: Disclaimer
Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co
Slide 4: Managing Directors' Message
Managing Directors’ Message Dear Investors We are pleased to declare the results for Q2FY26 as well as H1FY26. During H1FY26, while our revenue remained flat, margins saw a dip as API prices continued their downward trend. While IPM volumes remained muted, our CDMO business saw a volume growth of 7%
Slide 5: Two Decades' Legacy of Expertise, Experience & Trust
Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Quadria Capital Established R&D lab in Mumbai to manufacturing site for bought a minority Launched Akumentis to venture into regulated
Slide 6: Technologically Advanced Manufacturing Capabilities
Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 244 6 252 2.603 732 17 368 36 Ayurvedic / β-lac
Slide 7: R&D Focus
R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6
Slide 8: Key Highlights
OPN EAS) Key Highlights sti! Jd
Slide 9: Key drivers as well as their trends during Q2FY26
Key drivers as well as their trends during Q2FY26 Key drivers and their impact on Akums’ performance Strong volume Product mix API prices growth, though remains healthy Slower ramp up continue to market growth for H1, slight de- of new facilities remain soft remained flat growth in Q2 Driven by long
Slide 10: Formation of JV with Govt. of the Republic of Zambia
Formation of JV with Govt. of the Republic of Zambia Agreement Details Details of the project • The total project cost will be approx. USD 45 million, where • Government of The Republic of Zambia (GRZ) entered into a Akums will invest 51% and GRZ will invest 49% JV with Akums for establishment of a
Slide 11: Zambia pharmaceutical market is poised for growth with strong export potential
Zambia pharmaceutical market is poised for growth with strong export potential Domestic market poised for growth Strong potential for export • Zambia is a located in southern Africa and is part of the Southern African Development Community (SADC) region. • Population of around 22 million and is expe
Slide 12: Glimpses from the ground breaking ceremony
Glimpses from the ground breaking ceremony Aug’25 Oct’25 11 11
Slide 13: Europe – focused approach to drive next leg of growth
Europe – focused approach to drive next leg of growth European Infrastructure Capabilities Dosage form Capabilities • Audit completed for Plant 1 and Plant 2 • Sterile: Ampoules, Vials, FFS Large Volume Parental, • Plant 3 EU-GMP under renewal, ANVISA granted Respule, FFS Eye drops, DPI Penicillin •
Slide 14: Participation in CPHI Germany – Marking our presence in Europe
Participation in CPHI Germany – Marking our presence in Europe 13
Slide 15: Financial Performance Highlights
Q2 FY 26 Financial Performance Highlights 14
Slide 16: Quarterly Performance Highlights
Quarterly Performance Highlights Consolidated Performance* Segment Break-up Share in Q2 FY26 127 cr 43 cr Business Vertical revenue 1,050 cr 121 cr 54 cr 1,050 cr 12.1% 4.1% CDMO 79.0% 11.6% 5.1% Domestic Branded Total Income EBITDA PAT 12.0% Formulation Total Income (0.3% YoY) Adj. EBITDA (-79 bps
Slide 17: Half Yearly Performance Highlights
Half Yearly Performance Highlights Consolidated Performance* Segment Break-up 283 cr 107 cr Share in H1 FY26 2,101 cr Business Vertical revenue 121 cr 13.5% 54 cr 5.1% 1,050 cr CDMO 79.2% Total Income 11.6% Adj. EBITDA 5.1% Adj PAT (1.4% YoY) Domestic Branded (65 bps YoY) (-87 bps YoY) 11.2% Formula
Slide 18: Operating Performance Highlights
Operating Performance Highlights Particulars (Rs Cr) Q2 FY26 Q2 FY25 Y-O-Y (%) Q1 FY26 Q-O-Q (%) H1 FY26 H1 FY25 Y-O-Y (%) Revenue 1,018 1,033 -1.5% 1,024 -0.6% 2,042 2,052 -0.5% COGS 593 596 582 1,174 1,192 GP Margin % 41.8% 42.3% 43.2% 42.5% 41.9% Employee Expenses 189 180 176 365 356 Other Expens
Slide 19: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2 (INR Cr) Margin % Margin % 11.7% 12.0% 8.9% 12.6% 9.3% 6.4% 6.5% 4.1% 6.2% 4.1% -1.5% -22.0% -35.9 % 1033 1056 1024 1018 1010 129 121 121 67 66 65 94 94 44 43 Q2 FY 25Q3 FY 25Q4 FY 25Q1 FY 26Q2 FY 26 Q2 FY 25Q
Slide 20: Half-Yearly Performance Highlights
Half-Yearly Performance Highlights Revenue (INR Cr.) Adjusted EBITDA1 (INR Cr) Adjusted PAT2 (INR Cr) Margin % Margin % 12.0% 10.4% 10.9% 6.0% 5.2% 5.1% -0.5% -8.9% -13.4% 2052 2066 2042 245 215 223 124 110 107 H1 FY 25 H2 FY 25 H1 FY 26 H1 FY 25 H2 FY 25 H1 FY 26 H1 FY 25 H2 FY 25 H1 FY 26 (1 -Adju
Slide 21: Half-Yearly Performance Highlights
Half-Yearly Performance Highlights Working Capital (Days) Operating Cash Flow(1) (INR Cr) Adj ROE/ROCE(2) OCF/EBITDA % Net WC 109 91 91 28.9% 90.7% 88.8% Adj ROE 465 Adj ROCE 13.8% 101 102 101 13.1% 12.0% 84 11.2% 76 80 76 Debtors 68 67 8.7% Creditors 198 6.8% Inventory 71 H1 FY 25 FY 25 H1 FY 26 H1
Slide 22: Revenue and Margin Breakdown - Quarterly
Revenue and Margin Breakdown - Quarterly Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • CDMO growth slow on account of declining • Gross margins impacted due to unfavorable • Volume grew over 7% despite muted industry API prices. product mix in the quarter. growth • Trade Generics and API s
Slide 23: Revenue and Margin Breakdown – Half Yearly
Revenue and Margin Breakdown – Half Yearly Revenue (INR Cr.) Adj EBIDTA % CDMO Revenue (INR Cr.) • CDMO growth slow on account of declining • Impact on employee and other exp due to • Volume growth at 4% despite muted industry API prices. negative operating leverage on flat revenue. growth • Trade G
Slide 24: Segmental Quarterly Performance
Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue generics Revenue QoQ -1.1% YoY 0.7% QoQ 13.5% YoY 5.3% QoQ -36.0% YoY - 14.3% QoQ 5.3% YoY -26.2% QoQ -1.3% YoY -25.2% 799 813 804 116 122 33 107 35 59 23 24
Slide 25: Segmental Half-Yearly Performance
Segmental Half-Yearly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue generics Revenue YoY 2.3% YoY 4.4% YoY -4.9% YoY -23.7% YoY -30.7% 1618 1581 129 229 60 62 220 57 48 89 H1 FY 25 H1 FY 26 H1 FY 25 H1 FY 26 H1 FY 25 H1 FY 2
Slide 26: Thank You
Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: investors@akums.net/ankit.jain@akums.net Siddharth Rangnekar / Shruti Joshi CDR, India Tel: +91 97699 19966 / 75065 67349 Email: siddharth@cdr-india.com / shruti@cdr-india.com 25
Akums Drugs and Pharmaceuticals — H1 FY26 Earnings Presentation on 6ix